Replies to post #248326 on Avid Bioservices Inc (CDMO)

[biopharm]

itsabouttime, I'm glad you reminded everyone of this, because I think it is exactly part of the plan of expanding the label of Bavituximab. Why? ... because then it can be prescribed by other oncologists...etc when they are taking MANY other forms of treatment from chemo, irradiation, surgery..etc..etc that Bavituximab (PS Targeting) will help. Its all being scientifically proven now.

Sort of like a seatbelt, no matter what car you drive a seatbelt will help! Will the amount of money it costs Big Pharma be higher than what it costed auto manufacturers to add-in safety features ? we shall see... Seat-belts, air bags, sensors..etc..etc cost Auto Manufacturers Billions of dollars and I'm sure they liked it better without all those safety regulations.

The same exact thing is happening in Big Pharma now. For decades upon decades Big Pharma has been treating patients without adding any safety. Sort of sounds silly for why they didn't think of seat belts earlier.... and the same will be said years from now when there was no such thing as PS Targeting.

Imagine, all the posters on here today are literally (metaphor) trying to tell their 16 year old sons and daughters to hop on the expressway and don't wear a seat-belt! I know..... we are talking about cancer and not seat belts, but many industries go through paradigm shifts and Big Pharma is next.

--------------------------------------------------------------

itsabouttime:

Hutschi- we now can say...

The MOA of Bavi with its efficacy should not only increase eligibility of patients for treatment but improve quality,lower side effects,help elicit a curative regimen combined with
Yervoy an anti-CTLA-4 antibody.

Hutschi:

Important Safety Information for OPDIVO (nivolumab)and the OPDIVO+YERVOY Regimen

YERVOY® (ipilimumab) can cause serious side effects in many parts of your body which can lead to death. These serious side effects may include: intestinal problems (colitis) that can cause tears or holes (perforation) in the intestines; liver problems (hepatitis) that can lead to liver failure; skin problems that can lead to severe skin reaction; nerve problems that can lead to paralysis; hormone gland problems (especially the pituitary, adrenal, and thyroid glands); and eye problems.

These problems may happen anytime during treatment with YERVOY or after you have completed treatment. Your healthcare provider will check you for these problems during treatment with YERVOY. Your healthcare provider may treat you with corticosteroid medicines. Your healthcare provider should perform blood tests, such as liver, hormone, and thyroid function tests, before starting and during treatment with YERVOY. Your healthcare provider may need to delay or completely stop treatment with YERVOY if you have severe side effects.